Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Wellcome PLC

Division of GlaxoSmithKline PLC

Latest From Glaxo Wellcome PLC

Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms

Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.

Leadership Financing

Takeda Picks Next Big Thing In Immunotherapy: Gamma Delta T Cells

Takeda is aiming to get ahead in what it believes is an emerging area with big potential in immunotherapy: gamma delta T-cells. It has signed a deal with GammaDelta Therapeutics that gives it a purchase option on the UK-based, Abingworth-backed start-up. GammaDelta's CEO, former GSK executive Paolo Paoletti, and the head of Takeda's external innovation center, Dan Curran, spoke to Scrip.

Platform Technologies ImmunoOncology

Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss

Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.

Clinical Trials Regulation

Takeda’s Vaccine Business Aims High, Led By Former Gates Foundation Vaccine Director

Established in January 2012 on the foundation of Takeda’s long-standing domestic pediatric vaccine business, the new initiative will be global in scale, building on the territorial gains from the Nycomed acquisition, and led by a seasoned player.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Robert A Ingram, CEO
    J. D Coombe, Executive Dir., Fin & Investor Relations
    James Neidel, Executive Dir., R&D
    Richard Sykes, Chmn.
  • Contact Info
  • Glaxo Wellcome PLC
    Phone: (44) 1714 9340
    Lansdowne House
    Berkeley Square
    London, W1X 6BQ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register